ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Oct 11, 2017 10:15 JST
Source:
New Silkroutes Group Limited
New Silkroutes Group to Add More Clinics to Dental Portfolio to Further Expand Healthcare Business
Acquisition of The Dental Hub's 3 clinics will expand NSG's dental portfolio to 9 clinics and 2 dental supplies companies
SINGAPORE, Oct 11, 2017 - (ACN Newswire) - Healthsciences International Pte Ltd ("HSI"), through its fully owned subsidiary HSI Nominees A Pte Ltd, will pay approximately S$3.2 million to acquire a 70% stake in three dental clinics in Singapore as part of efforts to accelerate its growth. HSI is a subsidiary of New Silkroutes Group Limited ("NSG" or the "Group") and holds the Group's healthcare investments.
The move comes just four months after HSI completed the acquisition of majority control of six dental clinics and two dental supplies companies in Singapore in a major push to expand its healthcare capabilities. NSG acquired HSI in December 2016 in a deal that valued the healthcare company at S$4.25 million.
The three clinics to be acquired currently operate under The Dental Hub brand and are located at Bedok North Street 4, PSA Building at Alexandra Road, and Yew Tee Point at Choa Chu Kang. Collectively, they generated about S$2.7 million in revenue and S$0.5 million in earnings in their last financial year.
Following this acquisition, which is expected to be completed by 30 October 2017, HSI will have nine dental clinics and two dental supplies companies, making it one of the fastest-growing dental chains in Singapore.
Besides the dental business, HSI also has two clinics in Singapore providing complementary integrative therapies based on Western standards of medical care. HSI, in which NSG has a 69.35% stake, also operates clinic and pharmacy management systems in Singapore and China.
NSG will issue approximately 7.2 million new shares at 44 Singapore cents each as consideration for The Dental Hub clinics, which are currently equally owned by two dental practitioners, Dr Ainsley Toh and Dr Foong Siew Hong.
Dr Goh Jin Hian, NSG's Group Chief Executive Officer, said: "We are beginning to establish our healthcare services platform, which will eventually include medical specialist services and hospital management. Although we are starting with small steps in Singapore, HSI aspires to be a regional healthcare player in time to come."
New Silkroutes Capital Pte Ltd ("NSC"), a wholly owned subsidiary of NSG, will be responsible for raising funds to support the growth of HSI. NSC, the Group's financial services arm, is expanding its capabilities to focus on wealth management, investment banking, as well as private equity and venture capital financing in the energy, healthcare and real estate sectors.
About New Silkroutes Group Limited
New Silkroutes Group (Reuters: NEWS.SI; Bloomberg: NSG SP) is a Singapore-incorporated investment holding company listed on the Mainboard of Singapore Exchange Securities Trading Ltd (SGX). The group, through its subsidiaries and associate companies, focuses on these key sector verticals: Financials, Energy/Resources, Healthcare and Real Estate.
For enquiries, please contact:
New Silkroutes Group Limited
Email:
ipr@newsilkroutes.org
Source: New Silkroutes Group Limited
Sectors: Daily Finance, Healthcare & Pharm
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Toyota, Volvo Group and Daimler Truck AG sign binding agreement for Toyota to join cellcentric as equal shareholder
Jul 28, 2026 00:39 JST
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
Jul 27, 2026 23:50 JST
Launch of a proof-of-concept experiment for a next-generation distributed AI processing infrastructure aiming to realize the Watt-Bit vision
Jul 27, 2026 23:24 JST
Next-generation spectator experience at KYOJO CUP: AI selects and delivers "The moment you want to see" with ultra-low latency
Jul 27, 2026 22:40 JST
Sharp Acquires Vietnamese Corporation Engaged in Solar EPC And O&M Business as A Wholly Owned Subsidiary
Jul 27, 2026 22:02 JST
Collaboration Agreement announced by Sovereign Effects Partners to support GCAP
Jul 27, 2026 21:49 JST
Chunghwa Telecom, Fujitsu and 1Finity to accelerate All-Photonics Network deployment and advance quantum technologies in Taiwan through strategic partnership
Jul 27, 2026 21:08 JST
JCB and Fiuu Collaborate to Expand JCB Acceptance Across Southeast Asia
Jul 23, 2026 12:00 JST
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 18, 2026 00:24 JST
Hitachi and NVIDIA collaborate to advance HMAX and enable end-to-end autonomous operations through the integrated control of physical AI
Jul 17, 2026 23:35 JST
Toyota's First "BE creation" Spin-Off Begins Operations in Japan
Jul 17, 2026 23:00 JST
MHI Advances AI Infrastructure Commercialization with U.S. Deployment of 10MW-Class Chiller and MCP Development
Jul 17, 2026 22:47 JST
Noetra Launches Full-Scale R&D for Japan-Developed Multimodal Foundation Model
Jul 17, 2026 22:16 JST
Mitsubishi Motors Launches the Xforce HEV in Indonesia
Jul 17, 2026 21:47 JST
Fujitsu to explore physical AI development and implementation across industries with FANUC, Yaskawa Electric, and Kawasaki Heavy Industries integrating NVIDIA technology
Jul 17, 2026 21:05 JST
JCB Celebrates 30 Years of Trust, Honoring 70 Years of Japan-Philippines Friendship
Jul 17, 2026 10:00 JST
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Jul 16, 2026 22:00 JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Jul 16, 2026 00:18 JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 23:51 JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 23:21 JST
More Latest Release >>
Related Release
New Silkroutes Group sells its energy unit for US$10 million
March 25 2019 19:00 JST
New Silkroutes Group to Acquire 66% Stake in European Fund Manager Culross Global
October 19 2017 09:30 JST
New Silkroutes Group to Buy 8 Dental Clinics and 2 Dental Equipment Suppliers in Bid to Expand Healthcare Business
May 29 2017 09:00 JST
New Silkroutes Group Upgrades FY2017 Revenue Forecast for Oil Trading to US$400M from US$310M as Energy Unit turns in Another Strong Quarter
May 10 2017 09:00 JST
New Silkroutes Group Forms Joint-Venture Company for Real Estate Asset Management
March 01 2017 09:00 JST
New Silkroutes Group's Oil & Gas Unit Reports Highest-Ever Quarterly Revenue and Net Profit
February 13 2017 18:20 JST
New Silkroutes Group to Take 80% Stake in New York Broker-Dealer and Investment Bank CG Capital Markets for US$14.4m
February 03 2017 09:00 JST
New Silkroutes Group Signs MoU with Unit of Chinese Shipbuilder CSIC
October 18 2016 09:00 JST
New Silkroutes Group in Joint Venture to Offer Private Equity Funds in Asia Pacific
October 07 2016 09:00 JST
New Silkroutes Group to Expand into Healthcare in Asia with Acquisition of 51% Stake in Healthsciences International
September 15 2016 09:00 JST
More Press release >>